Phase 1
Safety, PK, Early PD
Early human studies produce noise before they deliver clarity. Signals are faint, confounders are everywhere, and timelines are unforgiving. Phase 1 requires analytics that can reveal patterns and relevance without losing the confidence of clinical teams.
What companies need at this stage
Teams require clean QC, early PD biomarkers, and rigorous modeling of confounders. They also need fast integration of clinical and molecular data to guide dose decisions and prepare Phase 2 with evidence.
BioLizard solutions
- QC and standardized pipelines.
- Mixed-effects models for biomarker interpretation.
- Confounder correction for batch, run, and site effects.
- Early MoA insights from integrated multi-omics.
- Clinical dashboards that help teams examine signals in real time.
Relevant Bio|Verse® modules
Bio|Verse® provides compliant infrastructure, traceability, and interactive views of biomarker trends and patient-level data for your clinical studies.
Explore →
Modular offerings
Clinical omics QC | Exploratory PD biomarker frameworks | Integrated transcriptomics and proteomics packages | Batch and technical correction modules
Explore all solutions →
Exploring target expression and identifying other indications with a similar mode of action
The client wanted to study the expression of their target gene within two known indications and to uncover other diseases where the target has a similar mode of action. Identifying comparable indications could strengthen the business case for further development. Our...
Identifying virulence factors in an opportunistic pathogenic bacterium
The client wanted to confirm and identify virulence factors in a gut bacterium that normally resides harmlessly in animals but can cause infection under stress or immunosuppression. Population structure complicated the distinction between pathogenic and commensal...
Unlocking immunogenicity insights from clinical reports with NLP
Most information about the immunogenicity of therapeutic peptides is locked in unstructured clinical reports. The client wanted to extract and structure this data to inform development of safe and effective treatments. Our Approach We built a robust extraction...